Literature DB >> 17135275

Involvement of hyperprolinemia in cognitive and psychiatric features of the 22q11 deletion syndrome.

Grégory Raux1, Emilie Bumsel, Bernadette Hecketsweiler, Therese van Amelsvoort, Janneke Zinkstok, Sylvie Manouvrier-Hanu, Carole Fantini, Georges-Marie M Brévière, Gabriella Di Rosa, Giuseppina Pustorino, Annick Vogels, Ann Swillen, Solenn Legallic, Jacqueline Bou, Gaelle Opolczynski, Valérie Drouin-Garraud, Marie Lemarchand, Nicole Philip, Aude Gérard-Desplanches, Michèle Carlier, Anne Philippe, Marie Christine Nolen, Delphine Heron, Pierre Sarda, Didier Lacombe, Cyril Coizet, Yves Alembik, Valérie Layet, Alexandra Afenjar, Didier Hannequin, Caroline Demily, Michel Petit, Florence Thibaut, Thierry Frebourg, Dominique Campion.   

Abstract

Microdeletions of the 22q11 region, responsible for the velo-cardio-facial syndrome (VCFS), are associated with an increased risk for psychosis and mental retardation. Recently, it has been shown in a hyperprolinemic mouse model that an interaction between two genes localized in the hemideleted region, proline dehydrogenase (PRODH) and catechol-o-methyl-transferase (COMT), could be involved in this phenotype. Here, we further characterize in eight children the molecular basis of type I hyperprolinemia (HPI), a recessive disorder resulting from reduced activity of proline dehydrogenase (POX). We show that these patients present with mental retardation, epilepsy and, in some cases, psychiatric features. We next report that, among 92 adult or adolescent VCFS subjects, a subset of patients with severe hyperprolinemia has a phenotype distinguishable from that of other VCFS patients and reminiscent of HPI. Forward stepwise multiple regression analysis selected hyperprolinemia, psychosis and COMT genotype as independent variables influencing IQ in the whole VCFS sample. An inverse correlation between plasma proline level and IQ was found. In addition, as predicted from the mouse model, hyperprolinemic VCFS subjects bearing the Met-COMT low activity allele are at risk for psychosis (OR = 2.8, 95% CI = 1.04-7.4). Finally, from the extensive analysis of the PRODH gene coding sequence variations, it is predicted that POX residual activity in the 0-30% range results into HPI, whereas residual activity in the 30-50% range is associated either with normal plasma proline levels or with mild-to-moderate hyperprolinemia.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17135275     DOI: 10.1093/hmg/ddl443

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  64 in total

Review 1.  The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders.

Authors:  Liam J Drew; Gregg W Crabtree; Sander Markx; Kimberly L Stark; Florence Chaverneff; Bin Xu; Jun Mukai; Karine Fenelon; Pei-Ken Hsu; Joseph A Gogos; Maria Karayiorgou
Journal:  Int J Dev Neurosci       Date:  2010-10-08       Impact factor: 2.457

2.  Genome-wide association study of NMDA receptor coagonists in human cerebrospinal fluid and plasma.

Authors:  J J Luykx; S C Bakker; W F Visser; N Verhoeven-Duif; J E Buizer-Voskamp; J M den Heijer; M P M Boks; J H Sul; E Eskin; A P Ori; R M Cantor; J Vorstman; E Strengman; J DeYoung; T H Kappen; E Pariama; E P A van Dongen; P Borgdorff; P Bruins; T J de Koning; R S Kahn; R A Ophoff
Journal:  Mol Psychiatry       Date:  2015-02-10       Impact factor: 15.992

Review 3.  Structure, function, and mechanism of proline utilization A (PutA).

Authors:  Li-Kai Liu; Donald F Becker; John J Tanner
Journal:  Arch Biochem Biophys       Date:  2017-07-14       Impact factor: 4.013

4.  Ohnologs are overrepresented in pathogenic copy number mutations.

Authors:  Aoife McLysaght; Takashi Makino; Hannah M Grayton; Maria Tropeano; Kevin J Mitchell; Evangelos Vassos; David A Collier
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-24       Impact factor: 11.205

5.  Diminished dosage of 22q11 genes disrupts neurogenesis and cortical development in a mouse model of 22q11 deletion/DiGeorge syndrome.

Authors:  Daniel W Meechan; Eric S Tucker; Thomas M Maynard; Anthony-Samuel LaMantia
Journal:  Proc Natl Acad Sci U S A       Date:  2009-09-10       Impact factor: 11.205

Review 6.  Neurobiological perspective of 22q11.2 deletion syndrome.

Authors:  Janneke R Zinkstok; Erik Boot; Anne S Bassett; Noboru Hiroi; Nancy J Butcher; Claudia Vingerhoets; Jacob A S Vorstman; Therese A M J van Amelsvoort
Journal:  Lancet Psychiatry       Date:  2019-08-05       Impact factor: 27.083

7.  PRODH rs450046 and proline x COMT Val¹⁵⁸ Met interaction effects on intelligence and startle in adults with 22q11 deletion syndrome.

Authors:  Mariken B de Koning; Esther D A van Duin; Erik Boot; Oswald J N Bloemen; Jaap A Bakker; Kathryn M Abel; Thérèse A M J van Amelsvoort
Journal:  Psychopharmacology (Berl)       Date:  2015-06-12       Impact factor: 4.530

Review 8.  Converging levels of analysis on a genomic hotspot for psychosis: insights from 22q11.2 deletion syndrome.

Authors:  Matthew J Schreiner; Maria T Lazaro; Maria Jalbrzikowski; Carrie E Bearden
Journal:  Neuropharmacology       Date:  2012-10-23       Impact factor: 5.250

9.  Palmitoylation-dependent neurodevelopmental deficits in a mouse model of 22q11 microdeletion.

Authors:  Jun Mukai; Alefiya Dhilla; Liam J Drew; Kimberly L Stark; Luxiang Cao; Amy B MacDermott; Maria Karayiorgou; Joseph A Gogos
Journal:  Nat Neurosci       Date:  2008-10-05       Impact factor: 24.884

10.  Peripheral amino Acid levels in schizophrenia and antipsychotic treatment.

Authors:  Vincenzo De Luca; Emanuela Viggiano; Giovanni Messina; Alessandro Viggiano; Carol Borlido; Andrea Viggiano; Marcellino Monda
Journal:  Psychiatry Investig       Date:  2008-12-31       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.